The Australian Medical Association Limited and state AMA entities comply with the Privacy Act 1988. Please refer to the AMA Privacy Policy to understand our commitment to you and information on how we store and protect your data.



04 Aug 2017

Another set of reports on health practitioners who receive payments from pharmaceutical companies will be published on 31 August this year.

Since August last year, details of such payments have been made publicly available every six months.

Since 1 October 2016, pharmaceutical companies have only been able to enter into relationships with health practitioners who consent to this information being published.

Medicines Australia member companies, which include innovative pharmaceutical companies such as Bayer, Pfizer and Janssen, published the first ever reports listing individuals and details of payments in 2016.

The current Medicines Australia Code of Conduct requires pharmaceutical companies to publish details of certain categories of payments made to registered health practitioners (such as medical practitioners, nurses and pharmacists).

The categories of payments that must be published include fees for speaking engagements, consultancies, board and committee attendance, and sponsorship or grants for educational activities.

The AMA fully supports these transparency measures.

During the first reporting period, individuals were able to withhold consent for their information to be made public in line with Australian privacy legislation. Around one third of practitioners receiving payments withheld their consent.

However, since 1 October 2016 that has no longer been possible.

A full list of the categories of payments publicly reported and the detail included in the reports is available on the AMA website at:

Links to each company’s first report are available on the Medicines Australia website at:



Published: 04 Aug 2017